Zenocutuzumab

Zenocutuzumab

Definition

A full-length IgG1 bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) directed against human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and human epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon intravenous administration of zenocutuzumab, the bispecific antibody docks on HER2, and subsequently blocks heregulin-stimulated proliferation of tumor cells by binding HER3. In addition to inhibiting HER3-dependent signaling, simultaneous targeting of HER2 and HER3 by zenocutuzumab may overcome a common resistance mechanism driven by heregulin-mediated dimerization of HER2 and HER3. Zenocutuzumab is expected to eliminate tumor cells by recruiting natural killer (NK) cells to tumor cells coated with the bispecific antibody.

Also known as Anti-HER2 x Anti-HER3 Bispecific Monoclonal Antibody MCLA-128, Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128, Bizengri, MCLA 128, MCLA-128, MCLA128, ZENOCUTUZUMAB, Zenocutuzumab-zbco — per NCIT

Also identified as

Indications

Disease Relation Source
Lung neoplasm may treat MEDRT · Public domain (U.S. Government work)
Small cell lung carcinoma may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Bronchi may treat a disease of this organ DERIVED · CC BY 4.0
Endocrine gland may treat a disease of this organ DERIVED · CC BY 4.0
Lungs may treat a disease of this organ DERIVED · CC BY 4.0

3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.